Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of “Moderate Buy” by Analysts

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) have received a consensus rating of “Moderate Buy” from the sixteen research firms that are covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and eleven have assigned a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $205.3571.

A number of brokerages have weighed in on CRL. Barclays upped their target price on Charles River Laboratories International from $200.00 to $210.00 and gave the stock an “overweight” rating in a research note on Tuesday. Weiss Ratings restated a “sell (d)” rating on shares of Charles River Laboratories International in a research note on Wednesday, January 21st. Royal Bank Of Canada began coverage on Charles River Laboratories International in a research note on Tuesday. They issued an “outperform” rating and a $215.00 target price on the stock. Wall Street Zen lowered Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Saturday, February 21st. Finally, Robert W. Baird set a $193.00 target price on Charles River Laboratories International in a research note on Thursday, February 19th.

Charles River Laboratories International Trading Up 0.7%

Shares of CRL stock opened at $179.54 on Wednesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.29. Charles River Laboratories International has a 52-week low of $99.80 and a 52-week high of $228.88. The company has a market capitalization of $8.86 billion, a PE ratio of -60.66, a price-to-earnings-growth ratio of 2.15 and a beta of 1.61. The business’s fifty day moving average is $169.06 and its 200 day moving average is $182.62.

Charles River Laboratories International (NYSE:CRL) last announced its earnings results on Wednesday, February 18th. The medical research company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.33 by $0.06. The business had revenue of $994.23 million for the quarter, compared to analyst estimates of $986.98 million. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, equities research analysts anticipate that Charles River Laboratories International will post 9.36 EPS for the current fiscal year.

Hedge Funds Weigh In On Charles River Laboratories International

Several institutional investors have recently modified their holdings of CRL. Tema Etfs LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $26,000. Rothschild Investment LLC increased its position in shares of Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 84 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Charles River Laboratories International during the 3rd quarter valued at about $31,000. Los Angeles Capital Management LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $42,000. Finally, Sfam LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at about $43,000. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.